Compare · ABT vs ASPE
ABT vs ASPE
Side-by-side comparison of Abbott Laboratories (ABT) and Aspen Neuroscience Inc. (ASPE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ASPE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $190.39B, about 526.3x ASPE ($361.7M).
- ABT has been more active in the news (13 items in the past 4 weeks vs 10 for ASPE).
- ABT has more recent analyst coverage (25 ratings vs 0 for ASPE).
- Company
- Abbott Laboratories
- Aspen Neuroscience Inc.
- Price
- -
- -
- Market cap
- $190.39B
- $361.7M
- 1M return
- +11.67%
- -
- 1Y return
- -12.96%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 13
- 10
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Aspen Neuroscience Inc.
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with high unmet medical need.
Latest ABT
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
- Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
- SEC Form 8-K filed by Abbott Laboratories
Latest ASPE
- SEC Form SCHEDULE 13D filed by Aspen Neuroscience Inc.
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- Director Thompson Peter A. converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)
- Director Orbimed Advisors Llc converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- Large owner Arch Venture Fund X, L.P. bought $19,999,995 worth of shares (1,333,333 units at $15.00) and converted options into 2,421,589 shares (SEC Form 4)
- Large owner Arch Venture Partners Xiv, L.P. bought $18,000,000 worth of shares (1,200,000 units at $15.00) (SEC Form 4)
- Director Spaventa Andrew converted options into 250,415 shares (SEC Form 4)
- Executive Chair Hasnain Faheem converted options into 36,349 shares (SEC Form 4)